Imagin Medical Receives Approval for 1st In-human Research Study

VANCOUVER, BC and BOSTON, MA--(Marketwired - September 27, 2017) - Imagin Medical, Inc. (CSE: IME) (CSE: IME.CN) (CNSX: IME) (OTC PINK: IMEXF) (FRANKFURT: DPD2) (the "Company") announced today that the University of Rochester (UR) Research Study Review Board (RSRB) has approved the first in-human study using the company's i/Blue Imaging System. Recruitment of subjects will begin immediately and continue until the study is completed, which is expected to be a 3-month process. More information can be found on www.clinicaltrials.com.

The pilot study entitled, Near Infrared Fluorescence Imaging for Bladder Cancer Detection, is sponsored by Dr. Edward Messing, Chair of Urology at the University of Rochester Medical Center, and the study's principal investigator. The primary purpose of the study is to determine the minimal dwell time needed for adequate detection of hexaminolevinulate HCL avid tumors using protoporphyrin IX (PpIX) near infrared fluorescence (NIRF).

The company has expressed confidence that the 10-patient study will validate previous bench-testing results that have shown 1) physicians will be able to "see" the cancer in 10 minutes vs. the full hour required by today's technology, and 2) the white and florescence images will blend into one to put the cancer into context within the bladder.

"We're very excited to receive the approval. It's a major milestone for Imagin and we're eager to see the study begin," said Jim Hutchens, Imagin's President and CEO. "Based on previous testing, we anticipate positive results that will bring us closer to delivering this life-saving technology to the marketplace."

About Imagin Medical
Imagin Medical is developing imaging solutions for minimally invasive surgical procedures where endoscopes are used. The Company believes it will radically improve the way physicians detect cancer and view the surgical field. Imagin's initial target market is bladder cancer, a major cancer worldwide, the sixth most prevalent in the U.S., and the most costly cancer to treat due to a greater than 50% recurrence rate. The ultrasensitive imaging technology is based upon improved optical designs and advanced light sensors. Learn more at www.imaginmedical.com

Information set forth in this news release contains forward-looking statements. These statements reflect management's current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.